Commentary

Video

Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC

Author(s):

Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).

Roger Li, MD, a genitourinary oncologist at Moffitt Cancer Center, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820) examining TAR-210 vs intravesical chemotherapy in patients with non–muscle-invasive bladder cancer.

Related Videos
Manali Kamdar, MD
Ibrahim Aldoss, MD
Laurence Albigès, MD, PhD
Joaquim Bellmunt, MD, PhD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
 Bernard H. Bochner, MD, FACS
Ana Christina Garrido-Castro, MD
Francisco Hernandez-Ilizaliturri, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Jean-Marc Classe, MD, PhD, Nantes Université